|1.||Schultz, Harold D: 2 articles (03/2014 - 01/2012)|
|2.||Schlenker, Evelyn H: 2 articles (03/2014 - 01/2012)|
|3.||Del Rio, Rodrigo: 1 article (03/2014)|
|4.||Ruiu, Stefania: 1 article (06/2002)|
|5.||Marchese, Giorgio: 1 article (06/2002)|
|6.||Bartholini, Francesco: 1 article (06/2002)|
|7.||Pani, Luca: 1 article (06/2002)|
|8.||Saba, Pierluigi: 1 article (06/2002)|
|9.||Gessa, Gian Luigi: 1 article (06/2002)|
|10.||Casti, Paola: 1 article (06/2002)|
|1.||Hypertension (High Blood Pressure)
02/01/1995 - "In an open study 15 patients with essential hypertension received 3 doses of carmoxirole, 0.5, 1 and 2 mg daily, each for a 2-week period, following a 2-week placebo phase. "
09/01/1992 - "Experimental evidence shows that carmoxirole lowers blood pressure in various models of hypertension mainly or exclusively through inhibition of noradrenaline release from sympathetic nerve endings. "
03/01/2014 - "Carmoxirole depressed frequency of breathing in euthyroid hamsters prior to, during and following hypoxia exposures and stimulated it in the hypothyroid hamsters following hypoxia. "
03/01/2014 - "Bromocriptine, but not carmoxirole (a peripheral D2 receptor agonist), increased oxygen consumption and body temperature in awake air-exposed hypothyroid female hamsters and stimulated their ventilation before and following exposure to hypoxia. "
01/15/2012 - "Relative to vehicle, carmoxirole and bromocriptine stimulated ventilation in the HH during and following exposure to hypoxia. "
06/28/2002 - "Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect."
06/28/2002 - "The concurrent administration of carmoxirole or bromocriptine completely reversed the hyperprolactinemia induced by amisulpride (0.5 mg/kg, s.c.) (ID(50)=14.9+/-0.8 mg/kg and 0.81+/-0.03 mg/kg, respectively). "
|2.||Neurotransmitter Agents (Neurotransmitter)
|3.||Dopamine D2 Receptors (Dopamine D2 Receptor)